Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0132 | 0.856 | 1 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0119 | 0.7282 | 1 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0067 | 0.2379 | 0.3267 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0067 | 0.2379 | 0.3267 |
Loa Loa (eye worm) | hypothetical protein | 0.0083 | 0.3912 | 0.3821 |
Loa Loa (eye worm) | hypothetical protein | 0.0072 | 0.2812 | 0.2359 |
Brugia malayi | Bromodomain containing protein | 0.0079 | 0.3479 | 0.2673 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0119 | 0.7282 | 1 |
Schistosoma mansoni | bromodomain containing protein | 0.0125 | 0.7918 | 1 |
Echinococcus granulosus | zinc finger protein | 0.0044 | 0.0152 | 0.0209 |
Loa Loa (eye worm) | hypothetical protein | 0.0087 | 0.4252 | 0.4272 |
Echinococcus multilocularis | zinc finger protein | 0.0044 | 0.0152 | 0.0209 |
Schistosoma mansoni | zinc finger protein | 0.0044 | 0.0152 | 0.0192 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 25.1189 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.